Bardet-Biedl Syndrome

Bardet-Biedl Syndrome (BBS) is a rare genetic condition that affects multiple parts of the body, with severe obesity being one of its most prominent features. People with BBS often experience insatiable hunger from an early age because the genetic mutation disrupts the brains ability to sense when the body has had enough food. The condition also affects vision, kidney function, and limb development, requiring coordinated care from multiple medical specialists throughout life.

Bardet-Biedl Syndrome is an autosomal recessive ciliopathy caused by mutations in at least 21 BBS genes (BBS1-BBS21) that impair primary cilia function. Hyperphagia and early-onset obesity result from disrupted leptin receptor signalling in hypothalamic neurons, which rely on intact ciliary transport. Diagnosis is clinical, based on primary features (rod-cone dystrophy, polydactyly, obesity, renal anomalies, hypogonadism, learning difficulties) with genetic confirmation. Setmelanotide, an MC4R agonist, is the first FDA-approved therapy targeting the underlying hyperphagia.

BBS represents one of the clearest examples of how genetic defects can directly drive severe obesity through disrupted appetite regulation, independent of lifestyle. Understanding rare genetic obesity syndromes like BBS helps clinicians at Accord Medical recognise when standard weight loss approaches may be insufficient and when targeted pharmacological intervention is needed.